Posatex

Antibacterial, anti-inflammatory, antifungal

For Otic Use in Dogs Only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Federal law prohibits the extralabel use of this drug in food-producing animals.

DESCRIPTION: Each gram of POSATEX^® Otic Suspension contains 10 mg of orbifloxacin; mometasone furoate monohydrate equivalent to 1 mg mometasone furoate; and 1 mg of posaconazole in a mineral oil based system containing a plasticized hydrocarbon gel.

Four drops of POSATEX^® Otic Suspension delivers approximately 1.0 mg orbifloxacin, 0.1 mg of mometasone furoate monohydrate, and 0.1 mg of posaconazole.

INDICATIONS: POSATEX^® Otic Suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa, and Enterococcus faecalis).

DOSAGE AND ADMINISTRATION: Shake well before use. For dogs weighing less than 30 lbs. instill 4 drops of POSATEX^® Otic Suspension once daily into the ear canal. For dogs weighing 30 lbs. or more, instill 8 drops once daily into the ear canal. Therapy should continue for 7 consecutive days.

CONTRAINDICATIONS: POSATEX^® Otic Suspension is contraindicated in dogs with known or suspected hypersensitivity to quinolones, mometasone furoate monohydrate, or posaconazole. Do not use in dogs with known tympanic perforation (see PRECAUTIONS).

PRECAUTIONS: The use of POSATEX^® Otic Suspension in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membranes should be confirmed before administering this product.

Avoid prolonged or repeated use of POSATEX^® Otic Suspension. Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see ANIMAL SAFETY).

The safe use of POSATEX^® Otic Suspension in dogs used for breeding purposes, during pregnancy or in lactating bitches, has not been evaluated. The systemic administration of quinolones has been shown to produce cartilage erosions of weight bearing joints and other signs of arthropathy in immature animals of various species.

ADVERSE REACTIONS: In the field study, 143 dogs were treated with POSATEX^® Otic Suspension. Of those, 1 dog with bilateral otitis externa developed hearing loss. POSATEX^® Otic Suspension treatment was discontinued and the condition resolved after one week.

To report suspected adverse reactions, call 1-800-224-5318.

For a copy of the Material Safety Data Sheet (MSDS) call 1-800-770-8878.

ANIMAL SAFETY: POSATEX^® Otic Suspension was administered at 1,3, and 5 times the recommended dosage for 21 consecutive days. The control group received the vehicle in both ears at the clinical dose given five times per day. There was a slight decrease in serum cortisol concentration after ACTH stimulation on Day 21 in the 5× group. Erythema was noted in all groups. Aural pain, swelling, or heat were each noted in 3 separate dogs in the 5× group.

STORAGE INFORMATION: Store at temperatures between 2°-30°C (35.6°-86°F).

Shake well before use.

HOW SUPPLIED: POSATEX^® Otic Suspension is available in 7.5 g, 15 g, and 30 g plastic bottles.

Approved by FDA under NADA # 141-266
Copyright© 2009, 2019 Intervet Inc., a subsidiary of Merck & Co. Inc.
Madison, NJ 07940 USA
All rights reserved.
Made in Germany
Rev. 02/2019

Posatex^®
Otic Suspension
(orbifloxacin, mometasone
furoate monohydrate and
posaconazole suspension)

Antibacterial,
Anti-inflammatory,
Antifungal

Caution: Federal law
restricts this drug to use by
or on the order of a licensed
veterinarian.

Federal law prohibits the
extralabel use of this drug
in food-producing animals.

KEEP OUT OF REACH
OF CHILDREN.

Approved by FDA under NADA # 141-266
NDC 0061-0089-03

30g

MERCK
Animal Health